UNDATED (AP) - Two studies suggest a first-of-its-kind osteoporosis drug lowers the risk of bone fractures as well as or better than current medicines.
The genetically engineered drug, called denosumab, was tested in older women and men with prostate cancer.
It's made by biotech company Amgen and is being reviewed this week by Food and Drug Administration advisers.
Wall Street sees it as a potential blockbuster crucial to Amgen's future. But given the many treatments for the bone-thinning disease, doctors see its expected high cost as a big drawback.
Denosumab is injected just under the skin just twice a year. If approved, it would compete against eight types of pills and injected medicines, including estrogen and generic and brand-name Fosamax.
Web Search powered by YAHOO!
|
LifestylesLifestyles
Studies: New osteoporosis drug cuts fracture risk
UNDATED (AP) - Two studies suggest a first-of-its-kind osteoporosis drug lowers the risk of bone fractures as well as or better than current medicines.
By:
|
WNCT
Published: August 11, 2009
Published: August 11, 2009
Email
Facebook
Google
Twitter
Favorites
MoreAdvertisement
View More:
Amgen,
Bone-Thinning Disease,
Food And Drug Administration,
Fosamax,
Health_Medical_Pharma,
Osteoporosis,
Prostate Cancer
Not what you're looking for? Try our quick search:
Reader Comments
*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.Deal of the Day
Advertisement
Interactive Radar
Advertisement
Featured Blogger
Reel Reviews
Updated: 02/10/2012
Nine On Your Side's Phillip Sayblack shares his take on the latest movie and dvd releases.
More Posts by Reel Reviews
Hot Topics on WNCT.com
Advertisement
Advertisement